WELL Health Technologies (TSE:WELL) reported second-quarter revenue of approximately C$404 million, up 12% from a year earlier, while adjusted EBITDA was C$48.1 million, down 3% on a reported basis. The company raised its full-year 2026 adjusted EBITDA outlook by C$10 million, citing stronger execut

Earnings event puts WELL Health Technologies under the microscope WELL Health Technologies (TSX:WELL) has stepped into the spotlight after reporting second quarter 2026 results that paired record quarterly revenue with a move from profit to loss. The company posted Q2 sales of CA$400.43 million compared with CA$356.67 million a year earlier, while net results shifted from income of CA$12.15 million to a net loss of CA$10.91 million. On a per share basis, basic and diluted loss from continuing...

WELL Health Technologies stock has delivered a steep decline of about 48.4% over the past 5 years, yet current valuation checks give a mixed reading rather than a clear bargain or clear overvaluation story. Recent news highlights record revenue milestones and new leadership hires, so investors are weighing that progress against a share price that has not kept pace. The share price is down roughly 48.4% over 5 years, which suggests long term holders have faced meaningful capital losses even...

Despite announcing strong earnings, WELL Health Technologies Corp.'s ( TSE:WELL ) stock was sluggish. Our analysis...